ACR 2022 Tweet by Dr. Antoni Chan

JAK and TYK-2 inhibitors and indications in SpA:

● Tofacitinib ➣ Pan JAKi (AS, PsA)
● Baricitinib ➣ JAK1,2
● Upadacitinib ➣ JAK1 (AxSpA, PsA)
● Deucravacitinib ➣ TYK2 (PsA)

Carol Langford, Year in Review #ACR22 @RheumNow